Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020136232 - IMMUNOSUPPRESSIVE M2 PROTEIN

Publication Number WO/2020/136232
Publication Date 02.07.2020
International Application No. PCT/EP2019/087059
International Filing Date 27.12.2019
IPC
C12N 15/86 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
CPC
A61K 2039/5256
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
525Virus
5256expressing foreign proteins
A61K 2039/577
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
57characterised by the type of response, e.g. Th1, Th2
577tolerising response
A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2710/24022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2710dsDNA Viruses
00011dsDNA Viruses
24011Poxviridae
24022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applicants
  • TRANSGENE SA [FR]/[FR]
Inventors
  • KLEINPETER, Patricia
  • MARCHAND, Jean-Baptiste
  • REMY, Christelle
Agents
  • REGIMBEAU
Priority Data
18306873.328.12.2018EP
19306023.321.08.2019EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IMMUNOSUPPRESSIVE M2 PROTEIN
(FR) PROTÉINE M2 À PROPRIÉTÉ IMMUNOSUPPRESSIVE
Abstract
(EN)
The invention is in the field of immunity and provides a poxviral polypeptide (referred here as M2 polypeptide) having the ability to bind B7-1 (CD80) and B7-2 (CD86) costimulatory molecules and modify their interactions with T cell surface receptors CD28, CTLA4 (for cytotoxic T-lymphocyte–associated antigen 4) and/or PD-L1(for programmed death-ligand 1). The present invention also relates to vector for expression of said poxviral M2 polypeptide and composition comprising said M2 polypeptide or expression vector for use as a new immunosuppressive drug as well as methods for treating diseases or disorders associated with non-adequate immune responses such as autoimmune diseases andtransplant rejections that comprise the administration of such a M2 polypeptide, M2-expressing vector or composition thereof (active agent). The present invention also relates to methods for producing such a M2 polypeptide.
(FR)
Polypeptide poxviral (dénommé polypeptide M2) ayant la capacité de se lier aux molécules costimulatrices B7-1 (CD80) et B7-2 (CD86) et de modifier leurs Interactions avec les récepteurs à la surface des lymphocytes T CD28, CTLA4 (pour l'antigène 4 associé aux lymphocytes T cytotoxiques) et/ou PD-L1 (ligand 1 de mort cellulaire programmée). La présente invention concerne également un vecteur d'expression dudit polypeptide M2 poxviral et une composition comprenant ledit polypeptide M2 ou un vecteur d'expression destiné à être utilisé en tant que nouveau médicament immunosuppresseur, ainsi que des procédés de traitement de maladies ou de troubles associés à des réponses immunitaires non adéquates telles que des maladies auto-immunes et des rejets de greffe incluant l'administration d'un tel polypeptide M2, d'un vecteur exprimant M2 ou d'une composition de celui-ci (agent actif). La présente invention concerne en outre des procédés de production d'un tel polypeptide M2.
Latest bibliographic data on file with the International Bureau